No Data
No Data
HeartBeam's Arrhythmia Assessment System Gains FDA 510(k) Clearance
Heartbeam Shares Are Trading Lower Amid a Possible Selloff. The Stock Initially Traded Higher After the Company Announced FDA Clearance for Its HeartBeam System, but It Has Since Reversed.
HeartBeam Stock Slips 15%
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology
Express News | HeartBeam Unveils Data At AHA 2024 For Portable Credit Card-Sized ECG Device; Studies Demonstrate Comparable Arrhythmia Detection To Standard ECGs And Highlight Remote Chest Pain Evaluation To Reduce Heart Attack Care Delays
HeartBeam Announces Positive Data From Two Studies at Prestigious American Heart Association Conference